Insulet Corporation (PODD) Sees Higher 2025–2026 Revenue and Operating Margins, Says Canaccord

Insulet Corporation (NASDAQ:PODD) ranks among the best medical device stocks to invest in. Canaccord Genuity maintained its Buy rating on Insulet Corporation (NASDAQ:PODD) and boosted its price target from $353 to $399 on September 29. In order to incorporate the latest investor conferences and revised revenue guidance into its model, the firm marginally raised its 2025 forward revenue expectations from $2.627 billion to $2.639 billion.

In addition to adding 100 basis points to the operating margin in 2025 and 2026, Canaccord has increased its 2026 revenue projection for Insulet Corporation (NASDAQ:PODD) from $3.033 billion to $3.046 billion.

Despite the revenue gains, Canaccord modified its net interest expense assumptions and dropped its earnings per share expectation to $5.74 from $6.09 and its 2026 operating income estimate to $549.3 million from $561.0 million.

Insulet Corporation (NASDAQ:PODD) is a global leader in tubeless insulin pump technology, offering innovative diabetes management solutions through its Omnipod Insulin Management System.

While we acknowledge the potential of PODD to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than PODD and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.